Dr. Dayan Goodenowe

Dr. Goodenowe is pioneering a new field of optimal health and longevity based on deep science and technology. This new field is the concept of biochemical reserve and moves beyond the focus of disease and prevention and towards true health and vitality. He is a neuroscientist and inventor. His research has made him an expert on the biochemical basis of disease. 

Image

Founder and CEO, Prodrome Sciences

Dr. Goodenowe’s research into the biochemical mechanisms of disease started in 1990. His curiosity about the biochemistry of life is as insatiable today as it was 30 years ago. In those 30 years, Dr. Goodenowe invented and developed advanced diagnostic and bioinformatic technologies, designed and manufactured novel and natural biochemical precursors, and identified biochemical prodromes of numerous diseases including Alzheimer’s disease and dementia, Parkinson’s disease, multiple sclerosis, stroke, autism, amyotrophic lateral sclerosis (ALS), multiple system atrophy, schizophrenia, bipolar disorder, depression, and cancers of the colon, pancreas, ovary, breast, lung, kidney, esophagus, liver, stomach, and endometria. At Prodrome Sciences, Dr. Goodenowe is going beyond the diagnosis of disease and has set his sights on figuring out how long the human body can maintain the physical and biological functions of life.

Video FAQs

Prodrome Sciences introduction

Dr. Dayan Goodenowe introduction and background

Death, disease, vitality, immortality

What is aging?

What is a prodrome?

The ProdromeScan blood test

The biomarkers measured with the ProdromeScan technology

ProdromeNeuro Plasmalogen Oil

Low blood plasmalogens and dementia

Low brain plasmalogens and dementia

Plasmalogens, aging, and death

What is a plasmalogen?

What do plasmalogens do?

Plasmalogens and neuroprotection

How to elevate plasmalogen levels

Plasmalogen supplementation

Plasmalogens and cognition deep dive

How plasmalogens are made and why people become deficient

SCIENTIFIC PRESENTATIONS

Dr. Goodenowe explains the history of plasmalogens from discovery to the development of plasmalogen oil supplements.

Dr. Goodenowe explains the biochemical basis of dementia and the causitive role of plasmalogens.

Dr. Goodenowe explains the science behind the APOE genotype, plasmalogens, and Alzheimer's disease.

RESEARCH PUBLICATIONS

Blood Tests

  1. Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence? Alzheimer's & Dementia TRCI 5: Doi 10.1016/j.trci.2019.08.003
  2. Relation of Serum Plasmalogens and APOE Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study. Brain Sci 9: Doi 10.3390/brainsci9040092
  3. Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study. BMC neurology, 15, 154. doi:10.1186/s12883-015-0411-4
  4. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 13: 416 Doi 10.1186/1471-2407-13-416
  5. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35: 59-62
  6. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48: 2485-2498 Doi 10.1194/jlr.P700023-JLR200
  7. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. World J Gastroenterol 21(21): 6604-6612
  8. Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer. Int J Cancer 132: 355-362 Doi 10.1002/ijc.27673
  9. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 2013, 13:416
  10. Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity. J Exp Clin Cancer Res 30: 59 Doi 10.1186/1756-9966-30-59
  11. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 8: 13 Doi 10.1186/1741-7015-8-13
  12. Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol 10: 140 Doi 10.1186/1471-230X-10-140
  13. Serum Metabolite Profiling for the Detection of Pancreatic Cancer: Results of a Large Independent Validation Study. Pancreas. 2016;45:1418-23.
  14. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013;13:416.

Dietary Supplements

  1. Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence? Alzheimer's & Dementia TRCI 5: Doi 10.1016/j.trci.2019.08.003
  2. Relation of Serum Plasmalogens and APOE Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study. Brain Sci 9: Doi 10.3390/brainsci9040092
  3. Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice. PLoS One. 2016 Mar 9;11(3):e0151020. doi: 10.1371/journal.pone.0151020.
  4. Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study. BMC neurology, 15, 154. doi:10.1186/s12883-015-0411-4
  5. Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res. 2015 Jun 1;286:328-37. doi: 10.1016/j.bbr.2015.03.012.
  6. Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease. Lipids in health and disease, 10, 227. doi:10.1186/1476-511X-10-227

Keep in touch

©2020 Prodrome Sciences Inc.

Search